What is Erasca?
Erasca is dedicated to the discovery, development, and commercialization of novel therapies targeting cancers driven by alterations in the RAS and MAPK pathways. These pathways are implicated in approximately 5.5 million new cancer diagnoses worldwide annually. The company's therapeutic strategy involves a holistic approach, aiming to comprehensively shut down the RAS/MAPK pathway through parallel targeting of multiple nodes and cooperative mechanisms. This focus on precision oncology positions Erasca at the forefront of innovative cancer treatment research.
How much funding has Erasca raised?
Erasca has raised a total of $564M across 3 funding rounds:
Series A
$64M
Series B
$200M
Share Placement
$300M
Series A (2019): $64M, investors not publicly disclosed
Series B (2020): $200M led by Terra Magnum Capital Partners, Invus, EDBI, Cormorant Asset Management , LLC, Colt Ventures, LifeSci Venture Partner, ARCH Venture Partners, and City Hill Ventures
Share Placement (2021): $300M, investors not publicly disclosed
Key Investors in Erasca
Invus
Invus is an investment firm specializing in financial advice, investment services, and consulting services, founded in 1985 and headquartered in New York City.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991, aiming to create value and empower businesses through strategic investments in areas like biotechnology and fintech.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs.
What's next for Erasca?
With the recent major strategic investment, Erasca is poised to advance its pipeline of precision oncology therapeutics. The substantial capital infusion, part of its $564M in total financing, will likely fuel further clinical development, research initiatives, and potential expansion of its therapeutic strategies. The company's focus on the frequently mutated RAS oncogene and the critical MAPK signaling pathway suggests a strategic direction towards addressing unmet needs in a significant patient population. This funding will be instrumental in Erasca's journey towards bringing potentially life-saving treatments to market.
See full Erasca company page
